Format

Send to

Choose Destination
FEBS Open Bio. 2018 Aug 1;8(9):1405-1411. doi: 10.1002/2211-5463.12493. eCollection 2018 Sep.

Off-target inhibition by active site-targeting SHP2 inhibitors.

Author information

1
Laura and Isaac Perlmutter Cancer Center NYU Langone Health New York NY USA.

Abstract

Due to the involvement of SHP2 (SH2 domain-containing protein-tyrosine phosphatase) in human disease, including Noonan syndrome and cancer, several inhibitors targeting SHP2 have been developed. Here, we report that the commonly used SHP2 inhibitor NSC-87877 does not exhibit robust inhibitory effects on growth factor-dependent MAPK (mitogen-activated protein kinase) pathway activation and that the recently developed active site-targeting SHP2 inhibitors IIB-08, 11a-1, and GS-493 show off-target effects on ligand-evoked activation/trans-phosphorylation of the PDGFRβ (platelet-derived growth factor receptor β). GS-493 also inhibits purified human PDGFRβ and SRC in vitro, whereas PDGFRβ inhibition by IIB-08 and 11a-1 occurs only in the cellular context. Our results argue for extreme caution in inferring specific functions for SHP2 based on studies using these inhibitors.

KEYWORDS:

11a‐1; GS‐493; IIB‐08; NSC‐87877; PDGFRβ; SHP2 inhibitor

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center